Comparison of main models of experimental colitis essential for studies on novel therapies of inflammatory bowel disease

Gastroenterologia Polska

Volumn 17, Issue 3, 2010, Pages 195-202

  Celiński, Krzysztof ^a   Dworzański, Tomasz ^a   Korolczuk, Agnieszka ^b   Słomka, Maria ^a   Radej, Sebastian ^b   Piasecki, Ryszard ^a   Czechowska, Grazyna ^a  

^a Klinika Gastroenterologii Uniwersytetu Medycznego W Lublinie   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

DSS; Experimental colitis; TNBS

Indexed keywords

ALCOHOL; DRINKING WATER; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLITIS; CONTROLLED STUDY; DISEASE COURSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; INFLAMMATION; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; RAT;

EID: 77956419132     PISSN: 12329886     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Celiński K., Dworzański T., Prozorow-Król B., Korolczuk A.: The role of PPAR-y receptors in gastrointestinal inflammation diseases. Gastroenterol. Pol., 2009, 16, 51-56.
2. Celiński K., Ma̧dro A., Prozorow-Król B., Korolczuk A., Cichoż-Lach H., Słomka M., Korobowicz E.: Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-γ)-specific agonist, as a modulator in experimental acute pancreatitis. Med. Sci. Monit., 2009, 15, 21-29.
3. Konturek P.C, Brzozowski T., Engel M., Burnat G., Gaca P., Kwiecień S., Pajdo R., Konturek S.J.: Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. J. Physiol. Pharmacol., 2009, 60, 41-47.
4. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., Blumberg R.S., Serhan C.N.: Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc. Natl. Acad. Sci. USA, 2005, 102, 7671-7676.
5. Ten Hove T., Corbaz A., Amitai H., Aloni S., Belzer I., Graber P., Drillenburg P., van Deventer S.J., Chvatchko Y., Te Velde A.A.: Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-α production. Gastroenterology, 2001, 121, 1372-1379.
6. Nakai M., Sudo K., Yamada Y., Kojima Y., Kato T., Saito K., Moriwaki H., Seishima M.: The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. Dig. Dis. Sci., 2005, 50, 1669-1676.
7. Matsuura M., Okazaki K., Nishio A., Nakase H., Tamaki H., Uchida K., Nishi T., Asada M., Kawasaki K., Fukui T., Yoshizawa H., Ohashi S., Inoue S., Kawanami C., Hiai H., Tabata Y., Chiba T.: Therapeutic effects of rectal administration of basic fibroblast growth factor on experimental murine colitis. Gastroenterology, 2005, 128, 975-986.
8. Coccia E.M., Remoli M.E., DiGiacinto C., Del Zotto B., Giacomini E., Monteleone G., Boirivant M.: Cholera toxin subunit B inhibits IL-12 and IFN-g production and signaling in experimental colitis and Crohn's disease. Gut, 2005, 54, 1558-1564.
9. Arafa H.M., Hemeida R.A., El-Bahrawy A.I., Hamada F.M.: Prophylactic role of curcumin in dextran sulfate sodium (DSS)-induced ulcerative colitis murine model. Food Chem. Toxicol., 2009, 47, 1311-1317.
10. Shimizu M., Zhao Z., Ishimoto Y., Satsu H.: Dietary taurine attenuates dextran sulfate sodium (DSS)-induced experimental colitis in mice. Adv. Exp. Med. Biol., 2009, 643, 265-271.
11. Brandl K., Rutschmann S., Li X., Du X., Xiao N., Schnabl B., Brenner D.A., Beutler B.: Enhanced sensitivity to DSS colitis caused by a hypomorphic Mbtps1 mutation disrupting the ATF6-driven unfolded protein response. Proc. Natl. Acad. Sci. USA, 2009, 106, 3300-5.
12. Reber S.O., Obermeier F., Straub R.H, Veenema A.H., Neumann I.D.: Aggravation of DSS-induced colitis after chronic subordinate colony (CSC) housing is partially mediated by adrenal mechanisms. Stress, 2008, 11, 225-234.
13. Chromik A.M., Müller A.M., Albrecht M., Rottmann S., Otte J.M., Herdegen T., Uhl W., Mittelkötter U.: Oral administration of taurolidine ameliorates chronic DSS colitis in mice. J. Invest. Surg., 2007, 20, 273-282.
14. Scheiffele F., Fuss I.J.: Induction of TNBS colitis in mice. Curr. Protocols. Immunol., 2001, 15.19.1-15.19.14.
15. Velde A., Marleen I., Verstege M., Hommes D.: Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm. Bowel Dis., 2006, 12, 995-999.
16. Camoglio L., te Velde A.A., de Boer A., ten Kate F.J., Kopf M., van Deventer S.J.: Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-gamma receptor-deficient mice. Eur. J. Immunol., 2000, 30, 1486-1495.
17. Hollenbach E., Vieth M., Roessner A., Neumann M., Malfertheiner P., Naumann M.: Inhibition of RICK/nuclear factor-kB and p38 signaling attenuates the inflammatory response in a murine model of Crohn disease. J. Biol. Chem., 2005, 280, 14981-14988.
18. Abad C., Martinez C., Juarranz M.G, Arranz A., Leceta J., Delgado M., Gomariz R.P.: Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology. 2003, 124, 961-971.
19. Tanaka T., Kohno H., Yoshitani S., Takashima S., Okumura A., Murakami A., Hosokawa M.: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res., 2001, 61, 2424-2418.
20. Kohno H., Suzuki R., Sugie S., Tanaka T.: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer, 2005, 5, 46.
21. Saubermann L.J., Nakajima A., Wada K., Zhao S., Terauchi Y., Kadowaki T., Aburatani H., Matsuhashi N., Nagai R., Blumberg R.S.: Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm. Bowel Dis., 2002, 8, 330-339.
22. Shah Y.M., Morimura K., Gonzalez F.J.: Expression of peroxisome proliferator-activated receptor-γ in macrophage suppresses experimental induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol., 2007, 292, 657-666.
23. Bassaganya-Riera J., Hontecillas R.: CLA and n-3 PUFA differentially modulate clinical activity and colonic PPAR-responsive gene expression in pig model of experimental IBD. Clin. Nutr., 2006, 25, 454-465.
24. Schaefer K.L., Denevich S., Ma C., Cooley S.R., Nakajima A., Wada K., Schlezinger J., Sherr D., Saubermann L.J.: Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm. Bowel Dis., 2005, 11, 244-252.
25. Yamamoto K., Ninomiya Y., Iseki M., Nakachi Y., Kanesaki-Yatsuka Y., Yamanoue Y., Itoh T., Nishii Y., Petrovsky N., Okazaki Y.: 4- Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor c agonist alleviates the symptoms of DSS-induced colitis. Biochem. Biophys. Res. Commun., 2008, 367, 566-572.
26. Dworzański T.: Wpływ agonisty (Rosiglitazon) i antagonisty (Badge) receptora PPAR-γ na przebieg eksperymentalnego zapalenia jelita grubego szczurów. Rozprawa doktorska, Uniwersytet Medyczny w Lublinie, Lublin, 2010.